PE20080145A1 - Tetrahidro-pirimidoazepinas como moduladores de trpv1 - Google Patents

Tetrahidro-pirimidoazepinas como moduladores de trpv1

Info

Publication number
PE20080145A1
PE20080145A1 PE2007000298A PE2007000298A PE20080145A1 PE 20080145 A1 PE20080145 A1 PE 20080145A1 PE 2007000298 A PE2007000298 A PE 2007000298A PE 2007000298 A PE2007000298 A PE 2007000298A PE 20080145 A1 PE20080145 A1 PE 20080145A1
Authority
PE
Peru
Prior art keywords
tetrahydro
phenyl
alkyl
pyrimidoazepine
trpv1
Prior art date
Application number
PE2007000298A
Other languages
English (en)
Inventor
Bryan James Branstetter
James Guy Breitenbucher
Michael D Lebsack
Jeffrey E Merit
Natalie A Hawryluk
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20080145A1 publication Critical patent/PE20080145A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

SE REFIERE A COMPUESTOS TETRAHIDRO-PIRIMIDOAZEPINA DE FORMULA (I), EN DONDE R1 ES H, -NRaRb, ALQUILO(C1-C6), -OALQUILO(C1-C6), -S-ALQUILO(C1-C6), CICLOALQUILO MONOCICLICO, ENTRE OTROS; R2 ES H, ALQUILO(C1-C6); R3 ES FENILO, BENCILO, PIRIDILO, PIRAZINILO, TIOFENILO, ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS CON Rg; Ar ES FENILO, PIRIDILO, IMIDAZOLILO, PIRIMIDINILO O HETEROARILO FUSIONADO BICICLICO OPCIONALMENTE SUSTITUIDO CON Rk. SON SELECCIONADOS: (4-TER-BUTIL-FENIL)-[7-(3-TRIFLUOROMETIL-PIRIDIN-2-IL)-6,7,8,9-TETRAHIDRO-5H-PIRIMIDO[4,5-d]AZEPIN-4-IL]-AMINA, N-INDAN-2-IL-N,N-DIMETIL-7-(3-TRIFLUORMETIL-PIRIDIN-2-IL)-6,7,8,9-TETRAHIDRO-5H-PIRIMIDO[4,5-d]AZEPIN-2,4-DIAMINA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON MODULADORES DE TRPV1 (PROTEINAS DE CANAL POTENCIAL RECEPTOR TRANSITORIO VAINILLOIDE) Y SON UTILES EN EL TRATAMIENTO DE DOLOR, PRURITO, TOS, ASMA Y ENFERMEDAD INFLAMATORIA DEL INTESTINO
PE2007000298A 2006-03-21 2007-03-19 Tetrahidro-pirimidoazepinas como moduladores de trpv1 PE20080145A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78541506P 2006-03-21 2006-03-21

Publications (1)

Publication Number Publication Date
PE20080145A1 true PE20080145A1 (es) 2008-02-11

Family

ID=38353855

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000298A PE20080145A1 (es) 2006-03-21 2007-03-19 Tetrahidro-pirimidoazepinas como moduladores de trpv1

Country Status (31)

Country Link
US (3) US8673895B2 (es)
EP (1) EP2024368B1 (es)
JP (1) JP5232768B2 (es)
KR (1) KR101461376B1 (es)
CN (1) CN101448835B (es)
AR (1) AR059985A1 (es)
AU (1) AU2007227203B2 (es)
BR (1) BRPI0709034B1 (es)
CA (1) CA2646977C (es)
CR (1) CR10387A (es)
DK (1) DK2024368T3 (es)
EA (1) EA017069B1 (es)
EC (1) ECSP088807A (es)
ES (1) ES2474152T3 (es)
HK (1) HK1129888A1 (es)
HR (1) HRP20140664T1 (es)
MX (1) MX2008012163A (es)
NI (1) NI200800253A (es)
NO (1) NO341676B1 (es)
NZ (1) NZ571343A (es)
PE (1) PE20080145A1 (es)
PL (1) PL2024368T3 (es)
PT (1) PT2024368E (es)
RS (1) RS53436B (es)
SG (1) SG177176A1 (es)
SI (1) SI2024368T1 (es)
TW (1) TWI440639B (es)
UA (1) UA92636C2 (es)
UY (1) UY30229A1 (es)
WO (1) WO2007109355A2 (es)
ZA (1) ZA200808975B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010381A1 (en) * 1996-09-04 1998-03-12 Intertrust Technologies Corp. Trusted infrastructure support systems, methods and techniques for secure electronic commerce, electronic transactions, commerce process control and automation, distributed computing, and rights management
US20080153845A1 (en) * 2006-10-27 2008-06-26 Redpoint Bio Corporation Trpv1 antagonists and uses thereof
AU2008231543B2 (en) * 2007-03-23 2011-07-28 Pfizer Limited Pyrimido [4, 5-D] azepine derivatives as 5-HT2C agonists
WO2009079000A1 (en) * 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolopyrimidine modulators of trpv1
WO2009078999A1 (en) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
TW201018681A (en) * 2008-07-31 2010-05-16 Genentech Inc Pyrimidine compounds, compositions and methods of use
CN102272133A (zh) * 2008-11-06 2011-12-07 阿斯利康(瑞典)有限公司 淀粉样β的调节剂
US20100331305A1 (en) * 2009-06-24 2010-12-30 Genentech, Inc. Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
US8828990B2 (en) * 2009-11-12 2014-09-09 Genentech, Inc. N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use
US8288381B2 (en) * 2009-11-12 2012-10-16 Genentech, Inc. N-9 substituted purine compounds, compositions and methods of use
US10167305B2 (en) 2010-06-23 2019-01-01 Johnson Matthey Public Limited Company Allyl complexes for use in coupling reactions
CN102154494B (zh) * 2011-03-14 2013-01-02 中国人民解放军军事医学科学院基础医学研究所 一种用于儿童哮喘检测的标志物
TWI582073B (zh) 2013-02-20 2017-05-11 Ｌｇ生命科學股份有限公司 鞘胺醇－１－磷酸酯受體促效劑、其製造方法及包含該促效劑作爲活性劑之醫藥組成物
CN103641762A (zh) * 2013-12-18 2014-03-19 中国药科大学 一类trpv1/cox-2双重抑制剂、其制备方法及其制备镇痛药物的用途
ES2964482T3 (es) 2019-12-03 2024-04-08 Lg Chem Ltd Agonista del receptor de esfingosina-1-fosfato, método de preparación del mismo y composición farmacéutica que comprende el mismo como agente activo

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160834A (en) * 1977-03-09 1979-07-10 Eli Lilly And Company 1-(Substituted benzoyl)-3-(substituted pyrazinyl)ureas
JPH03167178A (ja) 1989-11-24 1991-07-19 Taiji Nakayama ピリミジン誘導体
JPH03255077A (ja) 1990-03-01 1991-11-13 Taiji Nakayama ピリミジン誘導体およびそれを有効成分とする血小板凝集阻止剤
WO1993014080A1 (en) 1992-01-15 1993-07-22 E.I. Du Pont De Nemours And Company Bridged heterocyclic fungicides
JPH06172355A (ja) 1992-04-14 1994-06-21 Mect Corp ピリミジン誘導体およびそれを有効成分とする血小板凝集阻止剤
JP3167178B2 (ja) 1992-05-28 2001-05-21 積水化学工業株式会社 庇構造および庇カバー受材
JPH0625243A (ja) 1992-07-08 1994-02-01 Sankyo Co Ltd １−メチルカルバペネム誘導体の製造法
DE4332168A1 (de) 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19624069A1 (de) 1996-06-17 1997-12-18 Thomae Gmbh Dr K Benzazepinderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6150343A (en) * 1993-06-30 2000-11-21 University Of Pittsburgh Camptothecin analogs and methods of preparation thereof
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5834461A (en) * 1993-07-29 1998-11-10 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5428040A (en) 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
AR002459A1 (es) 1995-01-17 1998-03-25 American Cyanamid Co Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
WO1997019087A1 (en) 1995-11-17 1997-05-29 E.I. Du Pont De Nemours And Company Tricyclic herbicidal heterocycles
US6107300A (en) * 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
JP3531169B2 (ja) 1996-06-11 2004-05-24 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
AU3296497A (en) 1996-06-13 1998-01-07 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
AU6290998A (en) 1997-03-07 1998-09-29 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno{3,2-c}pyridine derivatives, their preparation and use
ZA982368B (en) * 1997-03-27 1998-09-23 Akzo Nobel Nv New therapeutic combinations
JP3255077B2 (ja) 1997-04-23 2002-02-12 日本電気株式会社 電話機
AU7445498A (en) 1997-06-25 1999-01-04 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US6358951B1 (en) * 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
JP2001097979A (ja) 1999-07-28 2001-04-10 Takeda Chem Ind Ltd 縮合複素環化合物、その製造法および用途
US7160890B2 (en) * 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
JP2001294572A (ja) 2000-02-09 2001-10-23 Dai Ichi Seiyaku Co Ltd 新規スルホニル誘導体
EP1149583A3 (en) * 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
DOP2001000154A (es) * 2000-05-25 2002-05-15 Pfizer Prod Inc Combinación de secretagogos de hormona del crecimiento y antidepresivos
ES2333097T3 (es) * 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
IL143690A0 (en) * 2000-06-19 2002-04-21 Pfizer Prod Inc The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
JP2004501917A (ja) * 2000-06-28 2004-01-22 ファイザー・プロダクツ・インク メラノコルチン受容体リガンド
IL143942A0 (en) * 2000-06-29 2002-04-21 Pfizer Prod Inc Use of growth hormone secretagogues for treatment of physical performance decline
EP1181933A3 (en) * 2000-06-29 2002-04-10 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating or increasing appetite
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
WO2002002518A2 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
US6369222B1 (en) 2000-07-18 2002-04-09 Hoffmann-La Roche Inc. mGluR antagonists and a method for their synthesis
AUPQ887100A0 (en) * 2000-07-19 2000-08-10 Dynamic Digital Depth Research Pty Ltd Image processing and encoding techniques
IL144468A0 (en) * 2000-07-27 2002-05-23 Pfizer Prod Inc Use of growth hormone secretagogues for improvement of functional health status
CA2422380C (en) * 2000-09-15 2009-03-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1192943A3 (en) * 2000-09-28 2002-11-27 Pfizer Products Inc. Use of growth hormone secretagogues in conjunction with physical exercise
NZ525324A (en) * 2000-10-20 2005-03-24 Eisai Co Ltd Nitrogenous aromatic ring compounds
CN100340555C (zh) * 2000-12-21 2007-10-03 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡唑化合物
WO2002051813A2 (en) 2000-12-27 2002-07-04 Merck Patent Gmbh PROCESS FOR THE PREPARATION OF α-AMINOSUBSTITUTED CARBOXYLIC ACID AMIDES
US7105667B2 (en) * 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
US6686352B2 (en) * 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
JP4397691B2 (ja) 2001-10-30 2010-01-13 コンフォーマ・セラピューティクス・コーポレイション Ｈｓｐ９０阻害活性を有するプリン類似体
ES2336435T3 (es) * 2001-11-30 2010-04-13 Schering Corporation Antagonista del receptor de adenosina a2a.
PL371587A1 (en) 2002-01-17 2005-06-27 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
US20030199514A1 (en) 2002-03-27 2003-10-23 Fryburg David A. Methods for improving efficacy of treatment with growth hormone secretagogues
AU2003242252A1 (en) * 2002-06-07 2003-12-22 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
US7384937B2 (en) * 2002-11-06 2008-06-10 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
MXPA05008309A (es) * 2003-02-10 2005-09-20 Amgen Inc Ligandos de receptor vaniloide y su uso en tratamientos.
AR045979A1 (es) * 2003-04-28 2005-11-23 Astrazeneca Ab Amidas heterociclicas
WO2004108120A1 (en) 2003-06-11 2004-12-16 Pfizer Products Inc. Use of growth hormone secretagogues for treatment of fibromyalgia
BRPI0412712A (pt) * 2003-07-21 2006-09-26 Pfizer Prod Inc compostos azapolicìclicos fundidos com heteroarila
US7968545B2 (en) * 2003-08-05 2011-06-28 Vertex Pharmaceuticals Inc. Compositions useful as inhibitors of voltage-gated ion channels
EP1655286A4 (en) 2003-08-08 2007-09-05 Sumitomo Chemical Co PROCESS FOR PRODUCING A LOW-FUSION CRYSTAL OF A FREE DISOPYRAMIDE BASE
JP2007520444A (ja) 2003-09-09 2007-07-26 ニューロジェン・コーポレーション 置換二環式キナゾリン−４−イルアミン誘導体
EP1670794A2 (en) 2003-09-30 2006-06-21 Amgen Inc. Vanilloid receptor ligands and their use in treatments
MXPA06003792A (es) 2003-10-07 2006-06-14 Astrazeneca Ab Nuevas 4-amino-tiazolo[4,5-d]-pirimidinas 2-sustituidas, utiles como antagonistas del receptor de quimiocina, especialmente cx3cr1.
US7816356B2 (en) * 2003-11-14 2010-10-19 Daniel Yohannes Aryl and heteroaryltetrahydrocyclobutapyrroles as nicotinic acetylcholine receptor ligands
US20070135454A1 (en) 2003-11-14 2007-06-14 Tracy Bayliss Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1)
JP2005162673A (ja) 2003-12-03 2005-06-23 Kyowa Hakko Kogyo Co Ltd 二環性ピリミジン誘導体
US7312330B2 (en) * 2003-12-24 2007-12-25 Renovis, Inc. Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
JP2007524673A (ja) * 2004-01-23 2007-08-30 アムジエン・インコーポレーテツド バニロイド受容体リガンドと治療におけるその使用
WO2005082865A1 (ja) * 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
US20080269238A1 (en) 2004-04-01 2008-10-30 Takeda Pharmaceutical Company Limited Thiazolopyrimidine Derivative
GB0412467D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
ITMI20041231A1 (it) 2004-06-18 2004-09-18 Pharmeste Srl Antagonisti del recettore dei vanilloidi trpv1
US7617501B2 (en) 2004-07-09 2009-11-10 Quest Software, Inc. Apparatus, system, and method for managing policies on a computer having a foreign operating system
ITMI20041566A1 (it) 2004-07-30 2004-10-30 Indena Spa "trpv1 agonisti, formulazioni che li contengono e loro usi"
FR2874015B1 (fr) 2004-08-05 2006-09-15 Sanofi Synthelabo Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
JP2006083085A (ja) 2004-09-15 2006-03-30 Kyowa Hakko Kogyo Co Ltd 二環性ピリミジン誘導体の製造法およびその合成中間体
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP2439207A1 (en) * 2004-10-04 2012-04-11 Millennium Pharmaceuticals, Inc. Lactam Compounds Useful as Protein Kinase Inhibitors
WO2006044762A2 (en) * 2004-10-15 2006-04-27 Bayer Pharmaceuticals Corporation Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor
CN102161653A (zh) 2004-11-24 2011-08-24 雅培制药有限公司 抑制香草素受体亚型1(vr1)受体的苯并二氢吡喃基脲化合物及其用途
US20060128710A1 (en) 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
CA2594998A1 (en) 2005-01-25 2006-08-03 Neurogen Corporation Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues
JP2008540633A (ja) 2005-05-18 2008-11-20 ファイザー・リミテッド バソプレッシン拮抗薬としての１，２，４−トリアゾール誘導体
PE20070171A1 (es) 2005-06-30 2007-03-08 Boehringer Ingelheim Int GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa
US20070032473A1 (en) * 2005-07-19 2007-02-08 Kai Gerlach Substituted amides and their use as medicaments
NZ565334A (en) * 2005-08-04 2010-12-24 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
WO2007047798A1 (en) * 2005-10-21 2007-04-26 Sensis Corporation Method and apparatus for providing secure access control for protected information
EP1951244A4 (en) 2005-11-22 2010-08-25 Glaxosmithkline Llc CALCILYTIC COMPOUNDS
JP4678685B2 (ja) 2005-12-26 2011-04-27 株式会社吉野工業所 エアゾール式液噴出器
DE102005062987A1 (de) 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
CA2637530A1 (en) 2006-01-18 2007-09-07 Siena Biotech S.P.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
EP1818330A1 (de) 2006-02-14 2007-08-15 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Prolinamide, deren Herstellung und deren Verwendung als Arzneimittel
US7795262B2 (en) * 2006-03-10 2010-09-14 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
WO2007109238A1 (en) 2006-03-21 2007-09-27 Schering Corporation Heterocyclic substituted pyridine compounds with cxcr3 antagonist activity
CA2652367A1 (en) 2006-05-16 2007-11-29 Merck & Co., Inc. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US20080051387A1 (en) 2006-06-09 2008-02-28 Yuelian Xu Tetrahydropyrido[3,4-d]pyrimidines and related analogues
JP2009007273A (ja) 2007-06-27 2009-01-15 Ajinomoto Co Inc ジアミノピリミジン化合物の製造方法
JP6025243B2 (ja) 2012-05-10 2016-11-16 富士フイルム株式会社 光電変換素子及びそれを用いた撮像素子
JP6172355B2 (ja) 2016-07-21 2017-08-02 富士ゼロックス株式会社 送受信システム及びプログラム

Also Published As

Publication number Publication date
KR101461376B1 (ko) 2014-11-26
WO2007109355A2 (en) 2007-09-27
AU2007227203B2 (en) 2013-01-10
RS53436B (en) 2014-12-31
CA2646977C (en) 2015-08-25
NI200800253A (es) 2012-11-30
AU2007227203A1 (en) 2007-09-27
US8673895B2 (en) 2014-03-18
US20140135311A1 (en) 2014-05-15
MX2008012163A (es) 2008-12-16
US9422293B2 (en) 2016-08-23
SI2024368T1 (sl) 2014-08-29
HK1129888A1 (en) 2009-12-11
JP2009530396A (ja) 2009-08-27
EP2024368A2 (en) 2009-02-18
DK2024368T3 (da) 2014-05-19
EP2024368B1 (en) 2014-04-30
EA200802020A1 (ru) 2009-04-28
SG177176A1 (en) 2012-01-30
BRPI0709034B1 (pt) 2022-05-31
KR20090006098A (ko) 2009-01-14
UA92636C2 (en) 2010-11-25
ZA200808975B (en) 2009-12-30
EA017069B1 (ru) 2012-09-28
ECSP088807A (es) 2008-11-27
US20070225275A1 (en) 2007-09-27
AR059985A1 (es) 2008-05-14
NO20084411L (no) 2008-11-03
BRPI0709034A2 (pt) 2011-06-21
PL2024368T3 (pl) 2014-09-30
CN101448835A (zh) 2009-06-03
HRP20140664T1 (hr) 2014-10-10
TWI440639B (zh) 2014-06-11
NZ571343A (en) 2011-09-30
WO2007109355A3 (en) 2007-11-15
PT2024368E (pt) 2014-07-17
CA2646977A1 (en) 2007-09-27
ES2474152T3 (es) 2014-07-08
NO341676B1 (no) 2017-12-18
CR10387A (es) 2009-02-23
CN101448835B (zh) 2012-06-27
UY30229A1 (es) 2007-07-31
US9738649B2 (en) 2017-08-22
TW200813061A (en) 2008-03-16
US20160318942A1 (en) 2016-11-03
JP5232768B2 (ja) 2013-07-10

Similar Documents

Publication Publication Date Title
PE20080145A1 (es) Tetrahidro-pirimidoazepinas como moduladores de trpv1
PE20080130A1 (es) Benzoimidazol-2-il pirimidinas y pirazinas como moduladores del receptor h4 de histamina
PE20080925A1 (es) DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO INHIBIDORES DE QUINASA, EN PARTICULAR INHIBIDORES IKK2 (O IKK BETA)
PE20081581A1 (es) COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
PE20070833A1 (es) Compuestos de pirimidinil benzotiofeno
PE20091211A1 (es) Derivados de pirazolopirimidina como moduladores de pde9a
PE20081370A1 (es) Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
PE20060585A1 (es) Derivados de 2-amido-4-feniltiazol como antagonistas de quimiocinas y su preparacion
PE20070619A1 (es) TIENO(2,3-b)PIRIDIN-5-CARBONITRILOS COMO INHIBIDORES DE PROTEINAS QUINASA
UY30183A1 (es) Derivados de quinolina
MX2007007103A (es) Derivados espiro como inhibidores de lipoxigenasa.
PE20090511A1 (es) Imidazopiridinonas
PE20141685A1 (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de transtornos inflamatorios
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
PE20120534A1 (es) PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt
PE20080348A1 (es) Moduladores tiazolopirimidina de trpv1
PE20081776A1 (es) Moduladores 2-aminopirimidina del receptor histamina h4
GEP20104962B (en) Fused heterocyclic compounds
PE20050081A1 (es) Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas
PE20080074A1 (es) Derivados de amida como agentes inhibidores de la quinasa c-fms
JO2770B1 (en) Organic compounds
PE20210154A1 (es) Derivados de piridincarbonilo y usos terapeuticos de los mismos como inhibidores de trpc6
PE20090435A1 (es) Inhibidores de tetrahidropiranocromeno de gamma secretasa
EA201070929A1 (ru) ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ

Legal Events

Date Code Title Description
FC Refusal